Stocks · Healthcare · Biotechnology
Taysha Gene Therapies, Inc. TSHA
$4.49 -3.02% Close, Oct 5, 2026 · NASDAQ · Market cap $1.48B
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -2792.3% from -1160.8% a year earlier.
- The diluted share count rose 23.8% in a year.
- Revenue over the last four quarters was $5.5M, down 32.3% from a year earlier, slowing from 3.4% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 14%
- Revenue growth, 3-year CAGRTop 12%
- Revenue growth accelerationBottom 8%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 38%
- Gross marginTop 26%
- Operating marginBottom 9%
- Accruals (lower is better)Bottom 32%
- Interest coverBottom 4%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 47%
- Free-cash-flow yieldBottom 38%
- EBITDA / enterprise valueBottom 34%
- Sales / enterprise valueBottom 6%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 46%
- 6-month returnBottom 39%
- 1-year return vs S&P 500Bottom 37%
- Distance from 52-week highBottom 41%
- Trend checklist (0–4)Bottom 36%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 39%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 38%
- Upside to consensus price targetTop 19%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 37%
- Maximum drawdown, 3 yearsBottom 47%
- Beta vs S&P 500 (lower is better)Bottom 4%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 3.4% | -32.3% | ↓ |
| Gross margin | 100.0% | 84.0% | ↓ |
| Operating margin | -1160.8% | -2792.3% | ↓ |
| FCF margin | -1019.2% | -2471.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -32.3% | 3.4% | ↓ | Bottom 14% |
| Gross margin | 84.0% | 100.0% | ↓ | Top 26% |
| Operating margin | -2792.3% | -1160.8% | ↓ | Bottom 9% |
| Net margin | -2728.0% | -1145.0% | ↓ | — |
| Free-cash-flow margin | -2471.7% | -1019.2% | ↓ | — |
| Return on invested capital | -34.5% | — | Bottom 38% | |
| Revenue growth, 3-year CAGR | 57.5% | — | Top 12% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -3.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 331.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -3646.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -18.01%
- Shareholder yield
- -18.01%
- Share count change, 1 year
- +23.8%
- Share count change, 3-year CAGR
- +79.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -1.9%
- Average 2-day reaction, last 8
- +0.6%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $14.00
- Target vs current price
- +211.8%
- Analysts with a rating
- 18
- Share rating Buy or Strong Buy
- 83%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | -14.8% | +4.9% | -2.5% | -14.0% | — |
| May 6, 2026 | -20.0% | +0.6% | -1.3% | -20.0% | -15.6% |
| Mar 19, 2026 | +27.3% | +2.5% | +2.9% | +33.7% | +28.3% |
| Nov 4, 2025 | +0.0% | -4.3% | -12.8% | -9.0% | +1.1% |
| Aug 12, 2025 | -28.6% | +5.4% | +6.2% | +18.8% | +54.7% |
| May 15, 2025 | +0.0% | +8.0% | +21.9% | +11.8% | +16.5% |
| Feb 26, 2025 | +12.5% | -4.7% | -4.1% | +4.1% | +70.0% |
| Nov 13, 2024 | -12.5% | -7.5% | -11.3% | +1.7% | -33.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.13 | -$0.11 | -14.8% | — |
| May 6, 2026 | -$0.12 | -$0.10 | -20.0% | — |
| Mar 19, 2026 | -$0.08 | -$0.11 | +27.3% | $5.5M |
| Nov 4, 2025 | -$0.09 | -$0.09 | +0.0% | — |
| Aug 12, 2025 | -$0.09 | -$0.07 | -28.6% | $2.0M |
| May 15, 2025 | -$0.08 | -$0.08 | +0.0% | $2.3M |
| Feb 26, 2025 | -$0.07 | -$0.08 | +12.5% | $2.0M |
| Nov 13, 2024 | -$0.09 | -$0.08 | -12.5% | $1.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 197.10× | — | — | Bottom 6% |
| Free-cash-flow yield | -9.15% | — | — | Bottom 38% |
| Earnings yield | -9.41% | — | — | Bottom 47% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.7%
- 200-day average slope (20 days)
- +0.2%
- Distance from 50-day average
- -19.8%
- Distance from 200-day average
- -17.6%
- RSI (14)
- 30.3
- Relative volume
- 0.93×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 62.6%
- Volatility vs own 5-year history
- 11th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.70
- Correlation with S&P 500
- 0.41
- Current drawdown from 1-year high
- -35.7%
- Maximum drawdown, 3 years
- -72.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 20, 2021 | Jun 28, 2023 | -98.1% | 613 days | Not yet recovered |
| Sep 28, 2020 | Dec 7, 2020 | -19.2% | 49 days | 11 days (Dec 22, 2020) |
| Dec 23, 2020 | Jan 6, 2021 | -10.7% | 8 days | 6 days (Jan 14, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.48B
- EPS, diluted (TTM)
- -$0.42
- Revenue (TTM)
- $5.5M
- 52-week range
- $3.69 – $7.30
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $2.5M | $15.5M | $8.3M | $9.8M |
| Gross profit | $0 | $14,999 | $15.5M | $8.3M | $9.8M |
| Operating income | -$173.3M | -$126.0M | -$72.4M | -$91.5M | -$110.5M |
| Net income | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| EPS (diluted) | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $2.0M | $2.3M | $2.0M | $0 | $5.5M | $0 | $0 |
| Net income | -$25.5M | -$18.8M | -$21.5M | -$26.9M | -$32.7M | -$27.9M | -$42.4M | -$46.6M |
| EPS (diluted) | -$0.10 | -$0.09 | -$0.08 | -$0.09 | -$0.09 | -$0.08 | -$0.12 | -$0.13 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$117.0M | -$88.4M | -$73.0M | -$81.2M | -$93.1M |
| Capital expenditure | -$21.6M | -$24.9M | -$7.4M | -$374,000 | -$738,000 |
| Free cash flow | -$138.6M | -$113.3M | -$80.4M | -$81.6M | -$93.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$360,000 | $53.2M | $140.8M | $76.8M | $265.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $455.4M
- Total assets
- $470.4M
- Total liabilities
- $83.2M
- Total debt
- $55.6M
- Net debt
- -$399.9M
- Shareholders’ equity
- $387.3M
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 51,405,384
- Days to cover
- 18.78
- Change vs previous report
- +9.8%
FINRA short interest, settlement date Sep 15, 2026.